BACKGROUND: Patients with HIV infection are at increased risk of cardiovascular disease (CVD). Vitamin D insufficiency has been associated with increased CVD risk in non-HIV populations. This study sought to determine the relationship between vitamin D status and markers of CVD and HIV-related factors in HIV-positive patients. METHODS: Patients with HIV infection on antiretroviral therapy and healthy controls were prospectively enrolled. Fasting lipids, glucose, insulin, inflammatory markers (soluble tumour necrosis factor-α receptor I, interleukin-6 and high-sensitivity C-reactive protein) and endothelial markers (soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1) were measured. Fasting 25-hydroxyvitamin D (25(OH)D) was measured from stored serum samples. The internal carotid artery and common carotid artery (CCA) intima-media thickness (IMT) were measured in a subset of HIV-positive patients. Baseline cross-sectional data were analysed. RESULTS: A total of 149 HIV-positive patients (56 with carotid IMT) and 34 controls were included. Controls had higher adjusted mean 25(OH)D levels than HIV-positive patients (P=0.02). In multivariable linear regression among the HIV-positive patients, 25(OH)D was positively associated with CD4(+) T-cell restoration after antiretroviral therapy (ΔCD4 = current - nadir CD4(+) T-cell; P<0.01), but was not associated with inflammatory or endothelial markers. In multivariable logistic regression, odds of having CCA IMT above the median were more than 10× higher in those with lower 25(OH)D levels (OR=10.62, 95% CI 1.37-82.34; P<0.01). CONCLUSIONS: Vitamin D status in HIV-positive patients was positively associated with improved immune restoration after antiretroviral therapy and negatively associated with CCA IMT. These findings suggest that vitamin D may play a role in HIV-related CVD and in immune reconstitution after antiretroviral therapy.
BACKGROUND:Patients with HIV infection are at increased risk of cardiovascular disease (CVD). Vitamin Dinsufficiency has been associated with increased CVD risk in non-HIV populations. This study sought to determine the relationship between vitamin D status and markers of CVD and HIV-related factors in HIV-positive patients. METHODS:Patients with HIV infection on antiretroviral therapy and healthy controls were prospectively enrolled. Fasting lipids, glucose, insulin, inflammatory markers (soluble tumour necrosis factor-α receptor I, interleukin-6 and high-sensitivity C-reactive protein) and endothelial markers (soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1) were measured. Fasting 25-hydroxyvitamin D (25(OH)D) was measured from stored serum samples. The internal carotid artery and common carotid artery (CCA) intima-media thickness (IMT) were measured in a subset of HIV-positive patients. Baseline cross-sectional data were analysed. RESULTS: A total of 149 HIV-positivepatients (56 with carotid IMT) and 34 controls were included. Controls had higher adjusted mean 25(OH)D levels than HIV-positive patients (P=0.02). In multivariable linear regression among the HIV-positive patients, 25(OH)D was positively associated with CD4(+) T-cell restoration after antiretroviral therapy (ΔCD4 = current - nadir CD4(+) T-cell; P<0.01), but was not associated with inflammatory or endothelial markers. In multivariable logistic regression, odds of having CCA IMT above the median were more than 10× higher in those with lower 25(OH)D levels (OR=10.62, 95% CI 1.37-82.34; P<0.01). CONCLUSIONS:Vitamin D status in HIV-positive patients was positively associated with improved immune restoration after antiretroviral therapy and negatively associated with CCA IMT. These findings suggest that vitamin D may play a role in HIV-related CVD and in immune reconstitution after antiretroviral therapy.
Authors: Mario Cozzolino; Marcos Vidal; Maria Vittoria Arcidiacono; Pablo Tebas; Kevin E Yarasheski; Adriana S Dusso Journal: AIDS Date: 2003-03-07 Impact factor: 4.177
Authors: Yan Chun Li; Guilin Qiao; Milan Uskokovic; Wei Xiang; Wei Zheng; Juan Kong Journal: J Steroid Biochem Mol Biol Date: 2004-05 Impact factor: 4.292
Authors: D A de Luis; P Bachiller; R Aller; J de Luis; O Izaola; M C Terroba; L Cuellar; M González Sagrado Journal: Nutr Hosp Date: 2002 Nov-Dec Impact factor: 1.057
Authors: Stephen M Arpadi; Donald McMahon; Elaine J Abrams; Marukh Bamji; Murli Purswani; Ellen S Engelson; Mary Horlick; Elizabeth Shane Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Thomas R Ziegler; Grace A McComsey; Jennifer K Frediani; Erin C Millson; Vin Tangpricha; Allison Ross Eckard Journal: AIDS Res Hum Retroviruses Date: 2014-07-16 Impact factor: 2.205
Authors: Kristine M Erlandson; Ivy Gudza; Suzanne Fiorillo; Buxton Ndemera; Robert T Schooley; Lovemore Gwanzura; Margaret Borok; Thomas B Campbell Journal: Int J Infect Dis Date: 2014-04-21 Impact factor: 3.623
Authors: Lediya T Cheru; Charles F Saylor; Kathleen V Fitch; Sara E Looby; Michael Lu; Udo Hoffmann; Takara L Stanley; Janet Lo Journal: Antivir Ther Date: 2019
Authors: Mariam Aziz; Britt Livak; Jane Burke-Miller; Audrey L French; Marshall J Glesby; Anjali Sharma; Mary Young; Maria C Villacres; Phyllis C Tien; Elizabeth T Golub; Mardge H Cohen; Oluwatoyin M Adeyemi Journal: AIDS Date: 2013-02-20 Impact factor: 4.177
Authors: Allison Ross Eckard; Mary Ann OʼRiordan; Julia C Rosebush; Joshua H Ruff; Ann Chahroudi; Danielle Labbato; Julie E Daniels; Monika Uribe-Leitz; Vin Tangpricha; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2017-12-15 Impact factor: 3.731